Antibodies, pharmaceutical compositions and methods
AssigneeObi Pharma, Inc.
InventorsCheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
Life of this patent
Estimating the term…
Loading patent…
AssigneeObi Pharma, Inc.
InventorsCheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
Estimating the term…
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
An antibody, or an antigen-binding fragment thereof, comprising:
An SSEA-4 binding antibody, or an antigen-binding fragment thereof, comprising:
An SSEA-4 antibody or binding fragment thereof, wherein the antibody or binding fragment thereof comprises VH selected from SEQ ID No:
An antibody, or an antigen-binding fragment thereof, produced by the hybridoma designated as 1J1s deposited under ATCC Accession Number PTA-122679.
A hybridoma designated as 1J1s deposited under ATCC Accession Number PTA-122679.
Dependencies are inferred from the claim text.